Canada markets open in 1 hour 55 minutes

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2750-0.0050 (-1.79%)
At close: 04:00PM EDT
0.2279 -0.05 (-17.13%)
Pre-Market: 07:29AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2800
Open0.2800
Bid0.0000 x 2200
Ask0.2298 x 800
Day's Range0.2641 - 0.2849
52 Week Range0.1750 - 0.7500
Volume1,053,381
Avg. Volume4,047,653
Market Cap50.463M
Beta (5Y Monthly)N/A
PE Ratio (TTM)1.15
EPS (TTM)0.2400
Earnings DateAug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split

    DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for t

  • GlobeNewswire

    Iterum Therapeutics Reports Second Quarter 2022 Financial Results

    --Enrollment in Registration Trial for uUTI to Begin Q4 2022-- --Cash Runway into 2024-- DUBLIN, Ireland and CHICAGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2022. “We are excited

  • GlobeNewswire

    Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA

    --SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN, Ireland and CHICAGO, July 11, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospit